A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

3期 进行中（已停止招募） NCT04221477

摘要

This study will evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab compared with placebo in participants with International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 class III or IV lupus nephritis (LN) when added on to standard-of-care therapy consisting of mycophenolate mofetil (MMF) and corticosteroids.

Percentage of Participants With Complete Renal Response (CRR)

At Week 76 · percentage of participants

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

• Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacok — Viatris Innovation GmbH
• Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With — Viatris Innovation GmbH
• Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults — Duke University
• Reducing Disparities in Medication Adherence in SLE — Duke University
• Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pa — Northwell Health
• COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders — National Institute of Allergy and Infectious Diseases (NIAID)

全部试验